These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20587884)

  • 1. Membranoproliferative glomerulonephritis secondary to chronic myeloid leukemia.
    Subramanian M; Kilara N; Manjunath R; Mysorekar V
    Saudi J Kidney Dis Transpl; 2010 Jul; 21(4):738-41. PubMed ID: 20587884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
    Campione E; Diluvio L; Paternò EJ; Di Marcantonio D; Francesconi A; Terrinoni A; Orlandi A; Chimenti S
    Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
    Mohamed AN; Pemberton P; Zonder J; Schiffer CA
    Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia.
    Bhagavathi S; Borromeo V; Desai H; Crisan D
    Ann Clin Lab Sci; 2008; 38(4):405-9. PubMed ID: 18988937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA; Pan Q; Ladanyi M; Steinherz PG
    Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
    Andrikovics H; Nahajevszky S; Szilvási A; Bors A; Adám E; Kozma A; Kajtár B; Barta A; Poros A; Tordai A
    Hematol Oncol; 2007 Sep; 25(3):143-7. PubMed ID: 17530620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
    Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
    Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy.
    Dwyer JP; Yates KM; Sumner EL; Stone WJ; Wang Y; Koury MJ; Fogo AB; Zent R
    Clin Nephrol; 2007 Mar; 67(3):176-81. PubMed ID: 17390742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
    Bueso-Ramos CE; Cortes J; Talpaz M; O'Brien S; Giles F; Rios MB; Medeiros LJ; Kantarjian H
    Cancer; 2004 Jul; 101(2):332-6. PubMed ID: 15241831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
    Mattiuzzi GN; Cortes JE; Talpaz M; Reuben J; Rios MB; Shan J; Kontoyiannis D; Giles FJ; Raad I; Verstovsek S; Ferrajoli A; Kantarjian HM
    Clin Cancer Res; 2003 Mar; 9(3):976-80. PubMed ID: 12631595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Johnson JR; Bross P; Cohen M; Rothmann M; Chen G; Zajicek A; Gobburu J; Rahman A; Staten A; Pazdur R
    Clin Cancer Res; 2003 Jun; 9(6):1972-9. PubMed ID: 12796358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.